Skip to content

Study · Not a test of the peptide alone · 2013

3 results

The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo.

Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW

JAMA dermatology1 Jan 2013Cited by 65 (Europe PMC)

PMID23407924 (opens in a new tab)DOI10.1001/2013.jamadermatol.386 (opens in a new tab)PepBankPUB-23407924
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01HumanNot a test of Melanotan I (afamelanotide) aloneCase report or seriesEfficacy outcome

    In 4 patients with generalized vitiligo, a regimen of afamelanotide implants plus narrowband UV-B induced faster and deeper repigmentation in each case.

    In plain wordsIn 4 people with vitiligo, afamelanotide implants combined with UV-B light treatment led to faster and deeper skin repigmentation.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseRepigmentation speed and depth in vitiligo
    Study

    n = 4

    Outcome group
    Pigmentation · Skin and wound

    Source sentences

    Summary
    Afamelanotide induced faster and deeper repigmentation in each case.
    2 context sentences
    Summary · context
    We describe the preliminary results of 4 patients with generalized vitiligo who developed repigmentation using afamelanotide in combination with narrowband UV-B (NB-UV-B) phototherapy.
    Summary · context
    Patients were treated 3 times weekly with NB-UV-B and starting in the second month received a series of 4 monthly implants containing 16 mg of afamelanotide.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  2. 02HumanNot a test of Melanotan I (afamelanotide) aloneCase report or seriesEfficacy outcome

    In 4 patients with generalized vitiligo, all had follicular and confluent areas of repigmentation within 2 days to 4 weeks after the first implant of the afamelanotide plus narrowband UV-B regimen.

    In plain wordsIn 4 people with vitiligo, all showed repigmented patches within 2 days to 4 weeks after the first implant, given with UV-B light treatment.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseFollicular and confluent repigmentation after first implant
    Study

    n = 4

    Outcome group
    Pigmentation · Skin and wound

    Source sentences

    Summary
    All patients experienced follicular and confluent areas of repigmentation within 2 days to 4 weeks after the initial implant, which progressed significantly throughout treatment.
    2 context sentences
    Summary · context
    We describe the preliminary results of 4 patients with generalized vitiligo who developed repigmentation using afamelanotide in combination with narrowband UV-B (NB-UV-B) phototherapy.
    Summary · context
    Patients were treated 3 times weekly with NB-UV-B and starting in the second month received a series of 4 monthly implants containing 16 mg of afamelanotide.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  3. 03HumanNot a test of Melanotan I (afamelanotide) aloneCase report or seriesEfficacy outcome

    In 4 patients with generalized vitiligo, all had diffuse hyperpigmentation during the afamelanotide plus narrowband UV-B regimen.

    In plain wordsIn 4 people with vitiligo, all had general skin darkening during afamelanotide implants combined with UV-B light treatment.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseDiffuse hyperpigmentation
    Study

    n = 4

    Outcome group
    Pigmentation · Skin and wound

    Source sentences

    Summary
    All patients experienced diffuse hyperpigmentation.
    2 context sentences
    Summary · context
    We describe the preliminary results of 4 patients with generalized vitiligo who developed repigmentation using afamelanotide in combination with narrowband UV-B (NB-UV-B) phototherapy.
    Summary · context
    Patients were treated 3 times weekly with NB-UV-B and starting in the second month received a series of 4 monthly implants containing 16 mg of afamelanotide.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.